Literature DB >> 7591256

Human T-cell-leukemia virus type I in post-transfusional spastic paraparesis: complete proviral sequence from uncultured blood cells.

A Bazarbachi1, M Huang, A Gessain, F Saal, A Saib, J Peries, H De Thé, F Galibert.   

Abstract

Human T-cell-leukemia virus type I (HTLV-I) is the causative agent of adult T-cell leukemia/lymphoma (ATL) and tropical spastic paraparesis/HTLV-I-associated myelopathy (TSP/HAM). The different disease outcome may be attributable to subtle mutations leading to modification of viral tropism or infectivity. Initial attempts found a very high level of sequence conservation among all HTLV-I strains. However, only one complete proviral DNA sequence is reported from a TSP/HAM patient, with a provirus derived from immortalized lymphocytes, which might be expected to be a leukemogenic variant rather than a neurotropic one. We cloned and sequenced a complete HTLV-I provirus (HTLV-IBoi) derived from the uncultured lymphocytes of a sub-acute post-transfusional TSP/HAM patient with clonal integration of HTLV-I. HTLV-IBoi proviral genome is 9033 bp long, and its overall genetic organization is similar to that of the prototype HTLV-I(ATK), without major deletions or insertions. No premature termination codon was found in the 4 open reading frames of the pX region. Divergence at the nucleotide level of HTLV-IBoi from the reported full-length HTLV-I varies from 1 to 9.4%, and indicates that it corresponds to a cosmopolitan genotype. This study did not identify specific sequences associated with neurotropic strains.

Entities:  

Mesh:

Year:  1995        PMID: 7591256     DOI: 10.1002/ijc.2910630406

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  8 in total

1.  Tax & rex: overlapping genes of the Deltaretrovirus group.

Authors:  Kathleen Margaret McGirr; Gertrude Case Buehuring
Journal:  Virus Genes       Date:  2006-06       Impact factor: 2.332

2.  African origin of human T-lymphotropic virus type 2 (HTLV-2) supported by a potential new HTLV-2d subtype in Congolese Bambuti Efe Pygmies.

Authors:  A M Vandamme; M Salemi; M Van Brussel; H F Liu; K Van Laethem; M Van Ranst; L Michels; J Desmyter; P Goubau
Journal:  J Virol       Date:  1998-05       Impact factor: 5.103

Review 3.  The origin and evolution of human T-cell lymphotropic virus types I and II.

Authors:  Y Suzuki; T Gojobori
Journal:  Virus Genes       Date:  1998       Impact factor: 2.332

4.  Molecular epidemiology of 58 new African human T-cell leukemia virus type 1 (HTLV-1) strains: identification of a new and distinct HTLV-1 molecular subtype in Central Africa and in Pygmies.

Authors:  R Mahieux; F Ibrahim; P Mauclere; V Herve; P Michel; F Tekaia; C Chappey; B Garin; E Van Der Ryst; B Guillemain; E Ledru; E Delaporte; G de The; A Gessain
Journal:  J Virol       Date:  1997-02       Impact factor: 5.103

5.  Phenotypic and genotypic comparisons of human T-cell leukemia virus type 1 reverse transcriptases from infected T-cell lines and patient samples.

Authors:  Michael S Mitchell; Ellen T Bodine; Shawn Hill; Gerald Princler; Patricia Lloyd; Hiroaki Mitsuya; Masao Matsuoka; David Derse
Journal:  J Virol       Date:  2007-02-07       Impact factor: 5.103

6.  In vivo genetic mutations define predominant functions of the human T-cell leukemia/lymphoma virus p12I protein.

Authors:  Risaku Fukumoto; Vibeke Andresen; Izabela Bialuk; Valentina Cecchinato; Jean-Claude Walser; Valerio W Valeri; Julie M Nauroth; Antoine Gessain; Christophe Nicot; Genoveffa Franchini
Journal:  Blood       Date:  2008-09-12       Impact factor: 22.113

7.  Complete genome sequence of Central Africa human T-cell lymphotropic virus subtype 1b.

Authors:  Louise Zanella; Koko Otsuki; Michel Abanto Marin; Izidro Bendet; Ana Carolina Vicente
Journal:  J Virol       Date:  2012-11       Impact factor: 5.103

Review 8.  Molecular epidemiology, genetic variability and evolution of HTLV-1 with special emphasis on African genotypes.

Authors:  Philippe V Afonso; Olivier Cassar; Antoine Gessain
Journal:  Retrovirology       Date:  2019-12-16       Impact factor: 4.602

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.